Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality

被引:27
作者
Krogh, Jesper [1 ]
Selmer, Christian [1 ]
Torp-Pedersen, Christian [2 ]
Gislason, Gunnar Hilmar [3 ]
Kistorp, Caroline [1 ]
机构
[1] Univ Copenhagen, Fac Hlth Sci, Herlev Univ Hosp, Dept Endocrinol, Copenhagen, Denmark
[2] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark
[3] Univ Copenhagen, Fac Hlth Sci, Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark
关键词
prolactin; morbidity; mortality; cohort-study; PROLACTIN LEVELS; SERUM PROLACTIN; INFLAMMATORY MARKERS; RISK; CABERGOLINE; HYPERPHAGIA; COMORBIDITY; PARAMETERS; ENDOCRINE; TRIAL;
D O I
10.1055/s-0043-107243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hyperprolactinemia has been suspected to increase mortality risk, but the available data are conflicting. The objective of this study was to estimate the association between hyperprolactinemia and all-cause and cardiovascular mortality among patients referred for assessment of prolactin. For this study, adults with no prio pituitary disease who underwent prolactin assessment at 3 university Hospitals in Denmark between 2001 and 2011 were included in a retrospective cohort study. A total of 3 633 patients with a median follow-up time of 5.3 years (IQR 2.7-5.7) were included. Mean (SD) age 39.7 (15.5) years and 78 % female. 373/3 633 (10.3 %) had hyperprolactinemia and during follow-up 330/3 633 (9.1 %) patients died of any cause, and 113/3 633 (3.1 %) patients died of cardiovascular causes. In males, hyperprolactinemia was associated with age-adjusted incidence rate ratio (IRR) of 1.86 for all-cause mortality (95 % CI 1.22-2.82) and 2.55 (95 % CI 1.43-4.55) for cardiovascular mortality. The IRR for all-cause mortality was reduced to 1.37 (0.90-2.08) when adjusted for the use of antipsychotic medication. The association between hyperprolactinemia and cardiovascular mortality remained after adjusting for confounders, for example, chronic renal failure, diabetes, and antipsychotic medication. In females, hyperprolactinemia was not associated with all-cause mortality (IRR 1.45; CI 0.86-2.47) or cardiovascular mortality (IRR 0.58; CI 0.14-2.39). In conclusion, hyperprolactinemia was associated with increased cardiovascular mortality in male patients. This association was not found in female patients. Focus on increased cardiovascular risk in males with hyperprolactinemia is warranted.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 36 条
[1]  
[Anonymous], 2011, INDIAN J ENDOCRINOL, DOI DOI 10.4103/2230-8210.83058
[2]   Effect of Cabergoline on Metabolism in Prolactinomas [J].
Auriemma, Renata S. ;
Granieri, Luciana ;
Galdiero, Mariano ;
Simeoli, Chiara ;
Perone, Ylenia ;
Vitale, Pasquale ;
Pivonello, Claudia ;
Negri, Mariarosaria ;
Mannarino, Teresa ;
Giordano, Carla ;
Gasperi, Maurizio ;
Colao, Annamaria ;
Pivonello, Rosario .
NEUROENDOCRINOLOGY, 2013, 98 (04) :299-310
[3]   Danish registers on personal income and transfer payments [J].
Baadsgaard, Mikkel ;
Quitzau, Jarl .
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2011, 39 :103-105
[4]   Focus on prolactin as a metabolic hormone [J].
Ben-Jonathan, N ;
Hugo, ER ;
Brandebourg, TD ;
LaPensee, CR .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2006, 17 (03) :110-116
[5]   Prolactin (PRL) in Adipose Tissue: Regulation and Functions [J].
Ben-Jonathan, Nira ;
Hugo, Eric .
RECENT ADVANCES IN PROLACTIN RESEARCH, 2015, 846 :1-35
[6]   Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy [J].
Berinder, Katarina ;
Nystrom, Thomas ;
Hoybye, Charlotte ;
Hall, Kerstin ;
Hulting, Anna-Lena .
PITUITARY, 2011, 14 (03) :199-207
[7]   Prolactin Levels, Endothelial Dysfunction, and the Risk of Cardiovascular Events and Mortality in Patients with CKD [J].
Carrero, Juan Jesus ;
Kyriazis, John ;
Sonmez, Alper ;
Tzanakis, Ioannis ;
Qureshi, Abdul Rashid ;
Stenvinkel, Peter ;
Saglam, Mutlu ;
Stylianou, Kostas ;
Yaman, Halil ;
Taslipinar, Abdullah ;
Vural, Abdulgaffar ;
Gok, Mahmut ;
Yenicesu, Mujdat ;
Daphnis, Eugene ;
Yilmaz, Mahmut Ilker .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (02) :207-215
[8]   Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels [J].
Ciresi, Alessandro ;
Amato, Marco Calogero ;
Guarnotta, Valentina ;
Lo Castro, Flavia ;
Giordano, Carla .
CLINICAL ENDOCRINOLOGY, 2013, 79 (06) :845-852
[9]   How to measure comorbidity: a critical review of available methods [J].
de Groot, V ;
Beckerman, H ;
Lankhorst, GJ ;
Bouter, LM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) :221-229
[10]   BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists [J].
dos Santos Silva, Cintia M. ;
Barbosa, Flavia R. P. ;
Lima, Giovanna A. B. ;
Warszawski, Leila ;
Fontes, Rosita ;
Domingues, Romeu C. ;
Gadelha, Monica R. .
OBESITY, 2011, 19 (04) :800-805